PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with hematological malignancies (HM) have a high risk of severe coronavirus disease 2019 (COVID-19), also in the Omicron period.
UNASSIGNED: Retrospective single-center study including HM patients with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) infection from January 2022 to March 2023. Study outcomes were respiratory failure (RF), mechanical ventilation (MV), and COVID-related mortality, comparing patients according to SARS-CoV2 serology.
UNASSIGNED: Note that, 112 patients were included: 39% had negative SARS-CoV2 serology. Seronegative were older (71.5 vs. 65.0 years, p = 0.04), had more often a lymphoid neoplasm (88.6% vs. 69.1%, p = 0.02), underwent anti-CD20 therapy (50.0% vs. 30.9% p = 0.04) and had more frequently a severe disease (23.0% vs. 3.0%, p = 0.02) than seropositive.Kaplan-Meier showed a higher risk for seronegative patients for RF (p = 0.014), MV (p = 0.044), and COVID-related mortality (p = 0.021). Negative SARS-CoV2 serostatus resulted in a risk factor for RF (hazards ratio [HR] 2.19, 95% confidence interval [CI] 1.03-4.67, p = 0.04), MV (HR 3.37, 95% CI 1.06-10.68, p = 0.04), and COVID-related mortality (HR 4.26, 95% CI 1.09-16.71, p = 0.04).
UNASSIGNED: : HM patients with negative SARS-CoV2 serology, despite vaccinations and previous infections, have worse clinical outcomes compared to seropositive patients in the Omicron era. The use of serology for SARS-CoV2 diagnosis could be an easy tool to identify patients prone to developing complications.
UNASSIGNED: Retrospective single-center study including HM patients with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) infection from January 2022 to March 2023. Study outcomes were respiratory failure (RF), mechanical ventilation (MV), and COVID-related mortality, comparing patients according to SARS-CoV2 serology.
UNASSIGNED: Note that, 112 patients were included: 39% had negative SARS-CoV2 serology. Seronegative were older (71.5 vs. 65.0 years, p = 0.04), had more often a lymphoid neoplasm (88.6% vs. 69.1%, p = 0.02), underwent anti-CD20 therapy (50.0% vs. 30.9% p = 0.04) and had more frequently a severe disease (23.0% vs. 3.0%, p = 0.02) than seropositive.Kaplan-Meier showed a higher risk for seronegative patients for RF (p = 0.014), MV (p = 0.044), and COVID-related mortality (p = 0.021). Negative SARS-CoV2 serostatus resulted in a risk factor for RF (hazards ratio [HR] 2.19, 95% confidence interval [CI] 1.03-4.67, p = 0.04), MV (HR 3.37, 95% CI 1.06-10.68, p = 0.04), and COVID-related mortality (HR 4.26, 95% CI 1.09-16.71, p = 0.04).
UNASSIGNED: : HM patients with negative SARS-CoV2 serology, despite vaccinations and previous infections, have worse clinical outcomes compared to seropositive patients in the Omicron era. The use of serology for SARS-CoV2 diagnosis could be an easy tool to identify patients prone to developing complications.
摘要：
■血液系统恶性肿瘤（HM）患者患严重冠状病毒病2019（COVID-19）的风险很高，也在Omicron时期。
■回顾性单中心研究，包括2022年1月至2023年3月患有严重急性呼吸道综合症冠状病毒2（SARS-CoV2）感染的HM患者。研究结果为呼吸衰竭（RF），机械通气(MV),和COVID相关死亡率，根据SARS-CoV2血清学比较患者。
■请注意，包括112例患者：39％的SARS-CoV2血清学阴性。血清学年龄较大（71.5vs.65.0年,p=0.04),更常见的是淋巴样肿瘤(88.6%vs.69.1%,p=0.02),接受抗CD20治疗（50.0%vs.30.9%p=0.04)，患有严重疾病的频率更高(23.0%vs.3.0%,p=0.02）比血清阳性。Kaplan-Meier显示血清阴性患者的RF风险较高（p=0.014），MV（p=0.044），和COVID相关死亡率（p=0.021）。SARS-CoV2血清状态阴性导致RF的危险因素（危险比[HR]2.19，95％置信区间[CI]1.03-4.67，p=0.04），MV（HR3.37，95%CI1.06-10.68，p=0.04），和COVID相关死亡率（HR4.26，95%CI1.09-16.71，p=0.04）。
■：SARS-CoV2血清学阴性的HM患者，尽管接种了疫苗和以前的感染，与Omicron时代的血清反应阳性的患者相比，临床结果更差。使用血清学诊断SARS-CoV2可能是识别容易发生并发症的患者的简单工具。
■回顾性单中心研究，包括2022年1月至2023年3月患有严重急性呼吸道综合症冠状病毒2（SARS-CoV2）感染的HM患者。研究结果为呼吸衰竭（RF），机械通气(MV),和COVID相关死亡率，根据SARS-CoV2血清学比较患者。
■请注意，包括112例患者：39％的SARS-CoV2血清学阴性。血清学年龄较大（71.5vs.65.0年,p=0.04),更常见的是淋巴样肿瘤(88.6%vs.69.1%,p=0.02),接受抗CD20治疗（50.0%vs.30.9%p=0.04)，患有严重疾病的频率更高(23.0%vs.3.0%,p=0.02）比血清阳性。Kaplan-Meier显示血清阴性患者的RF风险较高（p=0.014），MV（p=0.044），和COVID相关死亡率（p=0.021）。SARS-CoV2血清状态阴性导致RF的危险因素（危险比[HR]2.19，95％置信区间[CI]1.03-4.67，p=0.04），MV（HR3.37，95%CI1.06-10.68，p=0.04），和COVID相关死亡率（HR4.26，95%CI1.09-16.71，p=0.04）。
■：SARS-CoV2血清学阴性的HM患者，尽管接种了疫苗和以前的感染，与Omicron时代的血清反应阳性的患者相比，临床结果更差。使用血清学诊断SARS-CoV2可能是识别容易发生并发症的患者的简单工具。
